Thalidomide in patients with myelofibrosis with myeloid metaplasia.

被引：0
|
作者：
Barosi, G
Grossi, A
Comotti, B
Marchetti, M
机构：
[1] Policlin San Matteo, IRCCS, Lab Med Informat, I-27100 Pavia, Italy
[2] Policlin S Pietro, Hematol & Oncol Unit, Bergamo, Italy
[3] Policlin Careggi, Div Hematol, Florence, Italy
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3223
引用
收藏
页码：746A / 746A
页数：1
相关论文
共 50 条
  • [21] Clinical and bone marrow effects of α-interferon therapy in myelofibrosis with myeloid metaplasia.
    Tefferi, A
    Elliott, MA
    Yoon, SY
    Li, CY
    Mesa, RA
    Call, TG
    Dispenzieri, A
    BLOOD, 2000, 96 (11) : 745A - 745A
  • [22] Both B and T lymphocytes are clonally involved in myelofibrosis with myeloid metaplasia.
    Reeder, TL
    Bailey, RJ
    Dewald, GW
    Tefferi, A
    BLOOD, 2002, 100 (11) : 588A - 588A
  • [23] Unrelated hematopoietic stem cell transplantation (HSCT) for myelofibrosis with myeloid metaplasia.
    Koldehoff, M
    Basara, N
    Kiehl, MM
    Fauser, AA
    BLOOD, 2001, 98 (11) : 385B - 385B
  • [24] RARβ2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia.
    Jones, LC
    Tefferi, A
    Idos, GE
    Hofmann, WK
    Kumagai, T
    Koeffler, HP
    BLOOD, 2002, 100 (11) : 587A - 587A
  • [25] Urinary markers of angiogenesis and their correlation with intramedullary manifestations of angiogenesis in myelofibrosis with myeloid metaplasia.
    Mesa, R
    Kay, N
    Li, CY
    Bone, N
    Gray, L
    Tefferi, A
    BLOOD, 2002, 100 (11) : 347B - 347B
  • [26] Lenalidomide (CC-5013) treatment for anemia associated with myelofibrosis with myeloid metaplasia.
    Tefferi, A
    Mesa, RA
    Hogan, WJ
    Shaw, TA
    Reyes, GE
    Allred, JB
    Ma, CX
    Dy, GK
    Wolanskyj, AR
    Litzow, ML
    Steensma, DP
    Call, TG
    McClure, RF
    BLOOD, 2005, 106 (11) : 726A - 726A
  • [27] rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia.: Experience in 6 patients and meta-analytical approach
    Rodríguez, JN
    Martino, ML
    Diéguez, JC
    Prados, D
    HAEMATOLOGICA, 1998, 83 (07) : 616 - 621
  • [28] Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia
    Tefferi, A
    Elliott, MA
    BLOOD, 2000, 96 (12) : 4007 - 4007
  • [29] Antemortem presentation and management of non-hepatosplenic extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia.
    Houck, WA
    Mesa, RA
    Tefferi, A
    BLOOD, 2000, 96 (11) : 747A - 747A
  • [30] Bone marrow immunohistochemical studies of fibrogenic and angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia.
    Chou, JM
    Li, CY
    Tefferi, A
    BLOOD, 2002, 100 (11) : 590A - 590A
12345